GSK announces succession plan for cfo

Simon Dingemans joins from Goldman Sachs

Simon Dingemans has been named as chief financial officer designate and executive director of GlaxoSmithKline (GSK) from 4 January 2011. He will succeed Julian Heslop, who is to retire as chief financial officer and executive director of the company at the end of March 2011.

Dingemans joins the pharmaceutical firm from Goldman Sachs where he is currently managing director and partner. He has more than 25 years’ experience in investment banking, including most recently as leader of Goldman Sachs' European M&A business and before that as head of UK Investment Banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.

Dingemans has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.

Andrew Witty, chief executive of GSK, said: ‘Simon's appointment as cfo reflects the need for GSK to operate with both creativity and continued financial discipline. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model.’

You may also like

Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Finance

Curia invests $4m to enhance sterile API manufacturing

The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality
Finance

Agarose Bead Technologies marks 25 years with $10m global expansion plan

The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
Packaging

Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe

The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Finance

MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities

The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
Finance

Wilmington PharmaTech secures further funding for its expansion from Curewell Capital

The CDMO's partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the US
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Subscribe now